Abstract: Disclosed are methods for detecting pain in a subject, such as a mammal (e.g., a human), using brain activity, e.g., as determined by electroencephalography. The methods are useful for treating or reducing the likelihood of pain in a subject by determining power amplitude from the power spectral density of the waveforms and, e.g., administering a therapeutic agent to the subject. The methods disclosed herein may also be utilized to screen for a therapeutic agent that decreases power amplitude using a non-human animal subject. The methods also feature the stimulation of thalamic reticular nucleus of a subject to treat or reduce pain.
Abstract: The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the flexible infusion container, wherein the dosage form is ready-to-infuse and wherein the aqueous solution is stable at room temperature.
Abstract: Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection, in particular analgesics such as buprenorphine.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
July 13, 2021
Assignee:
Piedmont Animal Health Inc.
Inventors:
Douglas I. Hepler, Gail L. Dempsey, Dorothea Erxleben
Abstract: The present invention provides solid compositions of amorphous calcium carbonate (ACC) and a polyphosphate, bisphosphonate or pharmaceutical salts thereof as a stabilizer. Said stabilizers stabilizes the ACC and prevent crystallization to crystalline calcium carbonate ((?( (?) for a long period of time, even in an aqueous suspension. The invention further provides pharmaceutical composition comprising the solid ACC compositions as well their use in treating of certain diseases and conditions.
Type:
Grant
Filed:
June 2, 2016
Date of Patent:
July 6, 2021
Assignee:
AMORPHICAL LTD.
Inventors:
Yosef Ben, Yigal Dov Blum, Hagay Moshe, Ben Ashkenazi
Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.
Abstract: The present invention provides compositions comprising amorphous calcium carbonate (ACC), suitable to being administered by inhalation, and methods for their use in treating ACC-responsive diseases and conditions. Further provided are ACC compositions suitable for buccal or sublingual administration.
Abstract: The present invention relates to novel process for making oil-in-water nanoemulsions. The oil phase contains oil selected from the group consisting of triglyceride oil and/or petrolatum and a C8 to C16 fatty acid just be added during preparation; and the aqueous phase contains specific N-acyl derivatives of carboxylic amino acid as primary emulsifier.
Abstract: A pharmaceutical composition for aerosol administration and method of preventing or treating a pulmonary disease or condition in a subject with a SphK1 inhibitor are provided.
Type:
Grant
Filed:
November 24, 2015
Date of Patent:
June 8, 2021
Assignee:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Inventors:
Anantha Harijith, Viswanathan Natarajan, Roberto F. Machado, Jeffrey Jacobson
Abstract: Indoline sulfonamide compounds that can inhibit DapE and/or bacterial metallo-?-lactamases (MBLs), such as NDM-1, are disclosed. Also disclosed are methods of treating an individual suffering from a bacterial infection using the indoline sulfonamide compounds disclosed herein.
Type:
Grant
Filed:
July 17, 2019
Date of Patent:
June 1, 2021
Assignees:
LOYOLA UNIVERSITY OF CHICAGO, Board of Regents, The University of Texas System
Inventors:
Daniel Paul Becker, Tahirah K. Heath, Cory Reidl, Walter Fast
Abstract: A method of encapsulating cannabis-derived compounds in nanosized phospholipid vesicles is disclosed. A Cannabis sativa-derived formulation for transmucosal and transdermal delivery comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. Also disclosed herein are methods of transmucosal and transdermal administration of the formulation having phospholipid vesicles with nanoencapsulated Cannabis sativa-derived substances.
Abstract: The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? and one or more pharmaceutically acceptable excipient. It is produced by wet granulation techniques.
Abstract: It is provided a composition for controlled-release of volatile compounds comprising at least one poly(ethylene glycol) (PEG) polymer and one or more volatile compounds, the composition used for preserving food when incorporated in a food packaging. The volatile compounds are antimicrobial compounds such as allyl isothiocyanate (AITC), diacetyl, cinnamaldehyde, thymol, carvacrol and a combination thereof. The composition can comprise a blend of two or more PEG polymers of different molecular weights and/or a mixture of poly(lactic acid) (PLA) and poly(ethylene oxide) (PEO).
Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Type:
Grant
Filed:
April 3, 2020
Date of Patent:
April 27, 2021
Assignee:
NICOX OPHTHALMICS, INC
Inventors:
Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
Abstract: A method of treating non-infectious, inflammatory blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat the non-infectious, inflammatory blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.
Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.
Abstract: The purpose of present invention to provide a method for the production of an easy-to-take solid preparation, which is mainly characterized in that a coating processing for the easy-to-take property is simply performed by using a gelling agent in a dry process, without going through a wet condition, the easy-to-take solid preparation and the like.
Abstract: The purpose of present invention to provide a method for the production of an easy-to-take solid preparation, which is mainly characterized in that an outer layer-forming processing to provide an easy-to-take property is simply performed in a dry process without going through a wet condition so as to make the formed outer layer thicker; the easy-to-take solid preparation and the like.
Abstract: An aluminum-free antiperspirant/deodorant composition in the form of stick, cream, or flowable gel includes a carrier that includes a polyhydric alcohol or is a mixture of a polyhydric alcohol and water; a thickening agent including a C14-22 fatty acid salt; and an antiperspirant active and optionally a film-forming polymer dispersed in the carrier. The antiperspirant active is primarily a zinc-based antiperspirant active.
Type:
Grant
Filed:
December 7, 2017
Date of Patent:
March 2, 2021
Assignee:
Colgate-Palmolive Company
Inventors:
Peter Hilliard, Jr., Sharon Kennedy, Darrick Carlone, Cristina Bielli, Richard Adams
Abstract: The invention relates to a dental composition comprising a resin matrix, a filler matrix in an amount of at least 25 wt. % with respect to the weight of the dental composition, an initiator system, the resin matrix comprising polymerizable monomer(s) comprising two (meth)acrylate moieties connected to a brominated resorcinol, catechol, tyrosol, benzoic acid or phenol moiety. The invention relates also to a dental milling block comprising this composition in its hardened stage.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
March 2, 2021
Assignee:
3M INNOVATIVE PROPERTIES COMPANY
Inventors:
Adrian S. Eckert, Karsten Dede, Christoph H. Thalacker, Gioacchino Raia
Abstract: The present invention relates to dosage forms of gallium complexes suitable for oral delivery and methods of preparation thereof. Such dosage forms are useful for the treatment of diseases, including, but not limited to, cancer.
Type:
Grant
Filed:
October 8, 2019
Date of Patent:
March 2, 2021
Assignee:
Altum Pharmaceuticals Inc.
Inventors:
Rickey Roy Rhinebarger, Gina G. Stetsko